Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11

Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on Exagen (NASDAQ: XGN) and raised the price target from $9 to $11. This adjustment reflects a positive outlook for the company in the market.